Search Results
Your search for ,OUr matches 10643 pages
Showing 1851 - 1900Neoadjuvant Immunotherapy in Patients With Localized dMMR Colorectal Cancer
Investigators discovered that PD-1 inhibition prior to surgery may be effective for patients with localized mismatch repair–deficient or microsatellite instability–high (dMMR/MSI-H) colorectal cancer, according to a study published by Xiao et al in JNCCN–Journal of the National Comprehensive Cancer ...
New Scoring System Measures Inflammation Levels, May Improve Risk Stratification in AML
Researchers have discovered that severe inflammation may weaken the body’s ability to kill cancerous blood cells in patients with acute myeloid leukemia (AML), according to a new study published by Lasry et al in Nature Cancer. With bone marrow samples from 20 adults and 22 children with AML, the...
Risk Factors for Local Failure After Chemoradiation and MRI-Guided Brachytherapy for Locally Advanced Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Schmid et al identified risk factors for local failure in patients receiving chemoradiation and magnetic resonance imaging (MRI)-guided brachytherapy for locally advanced cervical cancer. Study Details The study used data from the EMBRACE-I...
Fewer Cases of Melanoma Found Among Individuals Taking Vitamin D Supplements
Fewer cases of melanoma were observed among individuals who regularly took vitamin D supplements than among those who did not take the supplements, according to a new study published by Kanasuo et al in Melanoma Research. Researchers also found that individuals taking vitamin D supplements...
Study Identifies Potential Molecular Differences Between Primary Breast Cancer and Its Metastases
Researchers have identified unique molecular features responsible for the development and progression of metastatic breast cancer, according to a novel study published by Garcia-Recio et al in Nature Cancer. They discovered that one of the key features involves changes in the immune system that are ...
Study Investigates Burden of Cervical Cancer Among Patients Aged 65 and Older
Researchers discovered that a significant number of patients aged 65 years and older may be facing late-stage cervical cancer diagnoses and disease-related mortality—despite U.S. Centers for Disease Control and Prevention (CDC) guidelines recommending that most patients stop screening for cervical...
Addition of Apalutamide May Slow Progression of Early-Stage Prostate Cancer During Active Surveillance
For patients with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggest findings from a preliminary clinical trial published by Schweizer et al in The Journal of Urology. "In our...
POLLUX Trial Final Overall Survival Analysis: Addition of Daratumumab to Lenalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues, the final overall survival analysis of the pivotal phase III POLLUX trial has shown a significant benefit with the addition of daratumumab to lenalidomide and dexamethasone after a median follow-up of...
Immune System B Cells May Help to Predict Treatment Response Among Patients With HER2-Positive Breast Cancer
Researchers have found that measuring the activation of immune system B cells may be more effective than measuring the activation of either T cells or tumor-infiltrating lymphocytes (TILs) in predicting whether patients with HER2-positive breast cancer will respond to treatment. These findings were ...
New AI-Based Biomarker May Help Predict Immunotherapy Response for Patients With NSCLC
Researchers have discovered a new artificial intelligence (AI)-derived biomarker that uses routine imaging scans to help predict which patients with non–small cell lung cancer (NSCLC) will respond to immunotherapy, according to a novel study published by Alilou et al in Science Advances. The...
Mitomycin Gel for Upper Tract Urothelial Cancers: Postmarket Analysis
Researchers have performed the first postmarkert analysis of a novel delivery system of mitomycin—a gel formation, also known as UGN-101—to treat upper tract urothelial cancers, according to a novel study published by Woldu et al in Urologic Oncology. Their findings showcase how the treatment is...
Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment and significantly improved antitumor responses in...
One in Seven Diagnosed Cancers Is Found by Recommended Screening Tests
Despite widespread awareness of the importance of screening for asymptomatic, early detection of cancer, screening tests exist for only five cancer types. With few recommended cancer screening tests and generally low adherence to cancer screening recommendations, it is difficult to detect cancer...
Uniting on Shared Priorities to Improve Cancer Care: ASCO and ECO Formalize Collaboration With a Memorandum of Understanding
ASCO and the European Cancer Organisation (ECO) are pleased to announce a new collaboration, formalized with a recently signed memorandum of understanding, that will advance their shared aims on cancer control. The two organizations will continue to work together to support the ECO-ASCO Special...
AACR and ASCO Release Joint Policy Statement on Electronic Nicotine Delivery Systems
The American Association for Cancer Research (AACR) and ASCO recently released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The...
Sotorasib Shows Clinically Meaningful Activity Among Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
The KRAS G12C inhibitor sotorasib demonstrated clinically meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C–mutated metastatic pancreatic cancer, accordi�ng to a novel study published by Strickler et al in The New England Journal of...
Study Examines Genitourinary Cancer Trends, Disparities in the United States
New findings revealed that the highest mortality rates for prostate cancer among White male patients were found in the Western United States—including California—despite low incidence rates, according to a new study published by Schafer et al in European Urology. However, when compared with White...
Eyal Gottlieb, PhD, to Join MD Anderson as Vice President for Research
The University of Texas MD Anderson Cancer Center recently announced that Eyal Gottlieb, PhD, has been named the institution’s Vice President for Research. In this role, Dr. Gottlieb will oversee laboratory science departments leading innovative discovery and translational research across a variety ...
A Lifelong Love of Science Leads to a Leadership Role in Oncology for Laurie Glimcher, MD
For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal...
Chronic Myelomonocytic Leukemia: Treatment and Prognosis, Part 2
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In the concluding half of this two-part installment, which began in our November 25 issue, Drs. Syed Ali Abutalib and Mrinal M. Patnaik continue to explore the current...
Expert Point of View: Joelle Fathi, DNP, RN, ARNP, CTTS, FAAN
An expert on the panel discussion of lung cancer screening from the Quantitative Imaging Workshop XIX, Joelle Fathi, DNP, RN, ARNP, CTTS, FAAN, Chief Healthcare Delivery Officer for the GO2 Foundation for Lung Cancer, called the lung cancer screening study a powerful reminder of the reality on the...
Managing Severe Diarrhea in Patients With Cancer
Diarrhea in patients with cancer is a well-known phenomenon with clear guidelines for prevention and management. However, it remains a condition with poorly explored consequences and a lack of sufficient and fast-acting treatments. In a webinar presented by members of the Multinational Association...
How ASCO and the Oncology Community Came Together to Discuss Progress in Global Cancer Control and the Challenges Ahead
After a 4-year in-person hiatus because of the COVID-19 global pandemic, the World Cancer Congress, hosted by the Union for International Cancer Control (UICC), held its first hybrid in-person and virtual meeting in October in Geneva. The conference brought together more than 2,000 attendees from...
World Cancer Research Fund International Launches New Flagship Research Program
The cancer prevention and survival research organization World Cancer Research Fund (WCRF) International recently launched the Global Cancer Update Programme, a new and updated version of the organization’s flagship research program, which was previously known as the Continuous Update Project. This ...
Risk-Reducing Bilateral Mastectomy May Help Women With High-Penetrance Genetic Mutations to Avoid Cancer
“Risk-reducing bilateral mastectomy allows a woman with a high-penetrance breast cancer-causing mutation to avoid an encounter with the experience of breast cancer diagnosis and treatment,” Seema A. Khan, MD, MPH, stated at the 2022 Lynn Sage Breast Cancer Symposium.1 For these women, by avoiding...
From the Clinic to the Lab: Overcoming Resistance to Immune Checkpoint Therapy
As a result of breakthroughs in immune checkpoint inhibitors over the past decade, immunotherapy has joined surgery, radiation therapy, and chemotherapy as one of the pillars of cancer treatment. However, nearly half of patients still do not benefit from immune checkpoint blockade. During the 2022...
Research Exposes Inequities in Health-Care Access and Delivery for Blood Disorders
Several studies presented during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition uncovered significant disparities in medical care and health outcomes among patients of different racial backgrounds, nationalities, and socioeconomic status across a range of blood...
Expert Point of View: Neelima Vidula, MD
Commenting on the DESTINY-Breast03 presentation at the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, a medical oncologist at Mass General Cancer Center, said: “The results highlight the important survival differences of T-DXd [fam-trastuzumab deruxtecan-nxki] compared to T-DM1...
How Telemedicine Can Transform Clinical Research and Practice
The COVID-19 pandemic transformed the world, and nowhere more so than in the health-care arena. Significant changes happened almost overnight in the delivery of medical care to focus on the safety and convenience of patients, staff, and providers. Although pilot efforts to integrate telemedicine...
How the American Cancer Society Aims to Improve Outcomes in Breast and Cervical Cancers and Reduce Health Disparities
Just days before the publication of the 2022 Annual Report to the Nation on the Status of Cancer on October 27, 2022,1 which showed a continued downward trend in cancer deaths, Karen Knudsen, MBA, PhD, Chief Executive Officer of the American Cancer Society (ACS), joined the First Lady Dr. Jill...
In Stage IV NSCLC, Anti-TIGIT Antibody Boosts Immunotherapy Benefit
In the phase II ARC-7 study, when domvanalimab, a novel antibody that blocks T-cell immunoglobulin and ITIM domain (TIGIT), was added to immunotherapy for patients with stage IV non–small cell lung cancer (NSCLC), the combination resulted in improved response rates and progression-free survival...
Study Finds Medicaid Expansion May Improve Survival Outcomes for Young Adult Patients With Cancer
Researchers have discovered that expanded Medicaid coverage under the Affordable Care Act may lead to better survival outcomes for young adult patients aged 18 to 39 years who have been newly diagnosed with cancer—particularly among those who identify as Hispanic or non-Hispanic Black—according to...
Quantifying the Population, Clinical, and Scientific Impact of NCTN Research
Clinical trials involving adult patients conducted within the National Cancer Institute’s National Clinical Trials Network (NCTN) over the past 4 decades are estimated to have extended the lives of U.S. patients with cancer by at least 14.2 million patient-years, according to a new study published...
Phase III NORA Study: Niraparib Maintenance Shows Favorable Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented by Mansoor Raza Mirza, MD, during the December Virtual ...
MD Anderson and WHO Establish a New International Collaboration to Reduce the Global Burden of Women’s Cancers
The University of Texas MD Anderson Cancer Center and the World Health Organization (WHO) recently announced a formal agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers. The agreement builds on years of collaboration between the...
Long-Term Follow-up of High-Dose Cytarabine and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
Long-term results of the phase III Mantle Cell Lymphoma Younger Trial were reported in the Journal of Clinical Oncology by Hermine et al. They showed a maintained advantage in time to treatment failure and an overall survival advantage with R-CHOP/R-DHAP (alternating rituximab plus...
Cedars-Sinai Cancer Leaders Assume New Roles
Lali Medina-Kauwe, PhD, former Co-Leader of the Cancer Biology Program in Cedars-Sinai Cancer, assumed a new role as Associate Director for Basic Research. The Cancer Biology Program will now be led by Dolores Di Vizio, MD, PhD, Professor of Biomedical Sciences, Pathology and Laboratory Medicine in ...
New Approaches Still Needed to Treat Patients With Cancer Who Have Serious Mental Illness
Although mandates by ASCO and the American Cancer Society to meet the needs of underserved populations have drawn much-needed awareness to the issue, patients with cancer who experience bipolar disorder, schizophrenia, and other debilitating mental illnesses continue to experience significantly...
Risk Model for Predicting the Development of Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Nyberg et al developed the risk model CanRisk-Prostate for predicting the development of prostate cancer based on age, detailed cancer family history, moderate- to high-risk pathogenic variants, and a polygenic score for common low-risk...
FDA Approves Pafolacianine to Aid Lung Cancer Surgery
The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors...
Risk of Adverse Side Effects From Cancer Immunotherapy May Be Higher in Patients With Certain Inherited Genetic Variations
Even as they’ve revolutionized cancer treatment, immune checkpoint inhibitors have been shown to produce a range of adverse immune-related side effects. Researchers have now identified inherited genetic variations that may place patients at high risk for complications when undergoing treatment with ...
From Immigrant Roots to a Budding Career in Oncology, Gladys Magaly Rodriguez, MD, Aims to Advance Health Equity in Vulnerable Populations
Gladys Magaly Rodriguez, MD, was born in Piedras Negras, Mexico, a city situated along the banks of the Rio Grande. At age 6, her family immigrated to Eagle Pass, Texas, a border town of some 30,000 people that is predominantly Latinx and Spanish speaking. “Even though I lived and attended school...
Alex Herrera, MD, Finds a Path From the Baseball Fields of Miami to a Leadership Role at City of Hope
Lymphoma expert Alex Herrera, MD, was born in Miami; his parents were just 19 years old when he was born. Dr. Herrera’s father was born in Puerto Rico to Cuban and Ecuadorian parents. His mother was born in Cuba and came to the United States via Operation Peter Pan, the clandestine program that...
Impact of Geriatric Assessment and Management on Quality of Life and Other Outcomes in Older Patients With Cancer
In the Canadian 5C study reported in the Journal of Clinical Oncology, Puts et al found that a geriatric assessment and management intervention did not improve quality of life, unplanned health-care use, mortality, or toxicity compared with usual care in patients aged 70 years or older with cancer. ...
Study Finds That Patients With Neuroendocrine Cancer and Doctors May Agree on Treatment Goals Only Half of the Time
Researchers revealed that patients with neuroendocrine cancer overwhelmingly prioritized quality of life over living longer, according to a new study published by Li et al in JNCCN–Journal of the National Comprehensive Cancer Network. The researchers surveyed 60 patients with advanced...
Bipartisan Comprehensive Cancer Survivorship Act Introduced
On December 14, U.S. Representative Mark DeSaulnier (D-CA), Representative Debbie Wasserman Schultz (D-FL), Senator Amy Klobuchar (D-MN), Senator Ben Cardin (D-MD), and Representative Brian Fitzpatrick (R-PA) introduced the Comprehensive Cancer Survivorship Act (CCSA)—legislation that will address...
Travel Time for Breast Cancer Screening May Remain Long for Many Patients, New Study Shows
Investigators revealed that the travel time to the nearest mammography facility may be long for a considerable proportion of patients in the United States, particularly affecting more than 50% of patients in the rural areas of 28 states, according to a new study published by Wiese et al in the...
Scientists Map Genetic Evolution of CLL to Richter Syndrome
Richter syndrome is an aggressive lymphoma that develops in up to 1% of patients with chronic lymphocytic leukemia (CLL) and it serves as an example of histologic transformation. While recent advances have transformed the treatment landscape of CLL, Richter syndrome remains associated with poor...
Zanubrutinib Found Superior to Ibrutinib for CLL and SLL
Zanubrutinib showed superior efficacy to ibrutinib—with fewer side effects—in the first head-to-head comparison between the Bruton’s tyrosine kinase (BTK) inhibitors among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to data presented by Jennifer...
Blinatumomab Further Improves Survival Among Patients With B-Lineage ALL and a Good Prognosis
The bispecific T-cell engager molecule blinatumomab was found to improve overall survival for patients with no measurable residual disease (MRD) after initial treatment for B-lineage acute lymphoblastic leukemia (ALL), according to the phase III ECOG-ACRIN E1910 trial presented by Litzow et al at...
